{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.37","value":"45.01"},{"groupId":"OG001","spread":"9.29","value":"45.54"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"556"},{"groupId":"OG001","value":"563"}],"units":"Participants"}],"title":"Lymphoma, Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.18","value":"2.04"},{"groupId":"OG001","spread":"7.46","value":"2.71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"509"},{"groupId":"OG001","value":"491"}],"units":"Participants"}],"title":"Lymphoma Change, Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.63","value":"2.99"},{"groupId":"OG001","spread":"8.36","value":"3.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"477"},{"groupId":"OG001","value":"478"}],"units":"Participants"}],"title":"Lymphoma Change, End Induction"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.29","value":"4.80"},{"groupId":"OG001","spread":"8.32","value":"4.52"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"360"},{"groupId":"OG001","value":"395"}],"units":"Participants"}],"title":"Lymphoma Change, Maint Month 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.34","value":"4.93"},{"groupId":"OG001","spread":"8.31","value":"4.27"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"360"},{"groupId":"OG001","value":"404"}],"units":"Participants"}],"title":"Lymphoma Change, Maint Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.81","value":"4.31"},{"groupId":"OG001","spread":"8.54","value":"4.57"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"407"},{"groupId":"OG001","value":"438"}],"units":"Participants"}],"title":"Lymphoma Change, End Maint"}],"denoms":[{"counts":[{"groupId":"OG000","value":"556"},{"groupId":"OG001","value":"563"}],"units":"Participants"}],"description":"The FACT-Lym Individual Subscale Lymphoma Score for the follicular lymphoma population was derived from the Lymphoma subscale questionnaire (range: 0-60). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received either 8 cycles of rituximab along with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (21-day cycle) or 8 cycles of rituximab along with 8 cycles of cyclophosphamide, vincristine, and prednisone (CVP) (21-day cycles) or 6 cycles of rituximab along with 6 cycles of bendamustine (28-day cycle) during the induction period. The induction period was followed by either a maintenance or observation period for responders or non-responders, respectively. Responders received rituximab monotherapy every 2 months for 2 years during the maintenance period. Non-responders received no protocol specified treatment during the 2-year observation period. Finally, participants were followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant was chosen by the site prior to initiation of the study.","id":"OG000","title":"Rituximab+Chemotherapy"},{"description":"Participants received either 8 cycles of obinutuzumab along with 6 cycles of CHOP (21-day cycle) or 8 cycles of obinutuzumab along with 8 cycles of CVP (21-day cycles) or 6 cycles of obinutuzumab along with 6 cycles of bendamustine (28-day cycle) during induction period. The induction period was followed by either a maintenance or observation period for responders or non-responders, respectively. Responders received obinutuzumab monotherapy every 2 months for 2 years during the maintenance period. Non-responders received no protocol specified treatment during the 2-year observation period. Finally, participants were followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant was chosen by the site prior to initiation of the study.","id":"OG001","title":"Obinutuzumab+Chemotherapy"}],"paramType":"MEAN","populationDescription":"The FL ITT population was defined as all randomized participants with follicular histology grouped according to their randomized treatment arm regardless of what treatments were actually received.","reportingStatus":"POSTED","timeFrame":"Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)","title":"Change From Baseline in FACT-Lym Individual Subscale Lymphoma Score (Follicular Population)","type":"SECONDARY","unitOfMeasure":"units on a scale"}